Clinical Associate Professor of Pharmacy Practice
Director of Pharmacy Addictions Research & Medicine Program
Bergen Brunswig Corporation Centennial Fellow
Lucas G. Hill graduated from the University of Missouri–Kansas City School of Pharmacy and completed a combined family medicine residency and faculty development fellowship at the University of Pittsburgh Medical Center. He is now a clinical associate professor at The University of Texas at Austin College of Pharmacy where he serves as director of the Pharmacy Addictions Research and Medicine (PhARM) Program and holds the Bergen Brunswig Corporation Centennial Fellowship. Dr. Hill is the principal investigator for a Texas Targeted Opioid Response project which seeks to address the opioid crisis in Texas by educating health professionals and conducting pragmatic research. He is an editorial board member for the Journal of the American College of Clinical Pharmacy and a past chair of the American Association of Colleges of Pharmacy Substance Use Disorder Special Interest Group. Dr. Hill has been recognized with several prestigious national awards, including the American College of Clinical Pharmacy New Educator Award and the American Pharmacists Association Generation Rx Award of Excellence.
National
American College of Clinical Pharmacy: New Educator Award (2021)
American College of Clinical Pharmacy Ambulatory Care PRN: Outstanding Paper of the Year (2021)
Journal of the American Pharmacists Association: Outstanding Peer Reviewer (2021)
American Pharmacists Association: Generation Rx Award of Excellence (2020)
American College of Clinical Pharmacy Ambulatory Care PRN: Outstanding Paper of the Year (2019)
Journal of the American Pharmacists Association: Outstanding Peer Reviewer (2019)
American Society of Health-System Pharmacists: CEO’s Award for Courageous Service (2018)
Regional
Austin Under 40 Awards: Finalist in Medicine & Healthcare (2021)
Austin Under 40 Awards: Finalist in Medicine & Healthcare (2020)
Texas Pharmacy Association: Generation Rx Champion Award (2018)
Local
UT College of Pharmacy: 10 Most Impactful Faculty (2022)
UT College of Pharmacy: Outstanding Faculty Advisor (2019)
UT College of Pharmacy: 10 Most Impactful Faculty (2018)
UT College of Pharmacy: William Arlyn Kloesel Outstanding Preceptor (2017)
UT College of Pharmacy: ATW Regional Outstanding Preceptor (2017)
UT College of Pharmacy: IPPE Outstanding Preceptor (2017)
Fellowships
Bergen Brunswig Corporation Centennial Fellowship (2021–Present)
Alumni Centennial Endowed Fellowship Advisor Award (2019–2020)
Alumni Centennial Endowed Fellowship Preceptor Award (2017–2018)
Honors
Journal of the American College of Clinical Pharmacy: #7 Most-Talked-About Paper (2021)
Twitter: Top 1000 Opioid Thought Leaders (2020)
UT School of Undergraduate Studies: Distinguished University Lecturer (2018)
Phi Lambda Sigma Pharmacy Leadership Society Inductee (2017)
Selected Television & Radio Interviews
KXAN Austin: Operation Naloxone – UT Austin library offering free doses of naloxone
KXAN Austin: Fentanyl overdoses dropped in 4 states. These solutions are helping.
KXAN Austin: Texas Longhorns linebacker Jake Ehlinger died of accidental overdose, family says
KCRW Los Angeles: Can you OD from touching fentanyl? How that myth gained a foothold among first responders.
FOX 7 Austin: CDC report – Drug overdose deaths hit record high in 2020
Texas Public Radio: Drug overdoses spiked during the pandemic. What’s fueling the surge?
CBS Austin: Texas AG’s office launches website to educate, prevent opioid misuse
CBS Austin: Austin billionaire named in new court filing for trying to shift blame for opioid addiction
KCBS San Francisco: Preventing overdose deaths on campus
NPR All Things Considered: On college campuses, making overdose medication readily available
Spectrum News Austin: Lone star crisis – the opioid epidemic
Spectrum News Austin: Capital Tonight – Trump unveils opioid plan
KXAN Austin: Advocates for painkiller addicts want society to meet them halfway
Spectrum News Austin: In Focus – The medication used to treat overdoses
NPR Marketplace: Overdose prevention on campus
Selected Print Interviews
Substance: Walmart is rejecting prescriptions and screwing over patients with addiction
TIME: Fewer than half of U.S. pharmacies carry one of the most effective drugs for opioid abuse
The Atlantic: An anti-overdose drug is getting stronger. Maybe that’s a bad thing?
VICE News: No, border patrol doesn’t need to be protected from fentanyl
Washington Post: A myth that lingers on – Casual contact with fentanyl causes overdoses
Inside Higher Ed: Wake-up call
Popular Science: The CDC says more prescriptions of overdose reversal drug naloxone are needed
Pharmacy Today: Fentanyl-related deaths spike, but pharmacists can reduce associated harm
Pharmacy Times: Pharmacists role in providing naloxone is expanding
Austin American-Statesman: “We are not immune” – how the opioid crisis is hitting Central Texas
Drug Topics: Four ways pharmacists are fighting opioid abuse
Houston Chronicle: Texas college students, fearing opioid deaths, teach each other to reverse overdoses
Alcalde: How Texas is trying to stay ahead of the opioid epidemic
The Daily Texan: Operation Naloxone given grant to service opioid addiction
The Daily Texan: College of Pharmacy combats opioid overdoses with campus campaign
*Hill LG, Light AE, Green TC, Burns AL, Sanaty Zadeh P, Freeman PR. (2022). Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists. J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.08.017.
Lai RK, Friedson KE, Reveles KR, Bhakta K, Gonzales G, Hill LG, *Evoy KE. (2022). Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review. J Am Pharm Assoc. DOI: 10.1016/j.japh.2022.07.008.
*Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel H, Peckham AM, Chen C, Ganetsky V, Yeung M, Zagorski CM, Reveles KR. (2022). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 237:109518. DOI: 10.1016/j.drugalcdep.2022.109518.
Gugala E, Briggs O, Moczygemba LR, Brown CM, *Hill LG. (2022). Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice. Subst Abus. 43(1):972-987. DOI: 10.1080/08897077.2022.2060423.
Loera LJ, *Hill LG, Zagorski CM, Jermain ML, Tirado CF. (2022). Description and evaluation of a pilot advanced pharmacy practice experience in addiction medicine. Am J Pharm Educ. 8926. DOI: 10.5688/ajpe8926.
White KM, *Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ. (2022). Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review. Subst Abus. 43(1):749-755. DOI: 10.1080/08897077.2021.2010161.
*Hill LG, Zagorski CM, Loera LJ. (2022). Increasingly powerful opioid antagonists are not necessary. Int J Drug Policy. 99:103457. DOI: 10.1016/j.drugpo.2021.103457.
*Evoy KE, Hill LG, Davis CS. (2021). Reply to letter to the editor regarding article: “Considering the potential benefits of over-the-counter naloxone”. Integr Pharm Res Pract. 10;77-78. DOI: 10.2147/IPRP.S327403.
*Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. (2021). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 116(6):1505-1511. DOI: 10.1111/ADD.15314.
*Bottner R, Weems J, Hill LG, Ziebell C, Long S, Young S, Sasser M, Ferguson A, Tirado C. (2021). Addiction treatment networks cannot withstand acute crises: Lessons from Winter Storm Uri in Texas. NAM Perspectives. DOI: 10.31478/202103c.
*Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH. (2021). Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. Am J Health Syst Pharm. 78(7):612-618. DOI: 10.1093/ajhp/zxab003.
*Evoy KE, Hill LG, Davis CS. (2021). Considering the potential benefits of over-the-counter naloxone. Integr Pharm Res Pract. 10:13-21. DOI: 10.2147/iprp.S244709.
*Coon SA, Hill LG, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, Tran TH, McFee Winans AR, Bratberg JP. (2020). Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks for the American College of Clinical Pharmacy. J Am Coll Clin Pharm. 3(8):1493-1513. DOI: 10.1002/jac5.1331.
*Tran T, Ball J, Bratberg JP, DeSimone EM, Franko TS, Hill LG, Koh-Knox Sharp CP, Palombi L, Ventricelli D, Farrell D, Gandhi N, Moore T. (2020). Report of the 2020 special committee on substance use and pharmacy education. Am J Pharm Educ. 84(11):8421. DOI: 10.5688/ajpe8421.
*Litten K, Hill LG, Garza A, Srinivasa M. (2020). Increasing naloxone knowledge and use through direct-to-patient education. J Pharm Technol. 36(6):237-242. DOI: 10.1177/8755122520954218.
*Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG. (2020). Opioid-related education provided by continuing education divisions at US pharmacy schools. Am J Pharm Educ. 84(10):8001. DOI: 10.5688/ajpe8001.
*Renfro ML, Loera LJ, Tirado CF, Hill LG. (2020). Lofexidine for acute opioid withdrawal: A clinical case series. Ment Health Clin. 10(5):259-263. DOI: 10.9740/mhc.2020.09.259.
*Zagorski CM, Myslinski JM, Hill LG. (2020). Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective. Int J Drug Policy. 86:102939. DOI: 10.1016/j.drugpo.2020.102939.
*Hill LG, Evoy KE, Reveles KR. (2020). Reply to a letter regarding, “Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction”. J Am Pharm Assoc. 60(5):e22-23. DOI: 10.1016/j.japh.2020.02.019.
*Mackert M, Pounders K, Brown L, Kirtz S, Hughes Wagner J, Ring D, Hill LG, Wilcox G, Murthy D, Tierney W, Innerarity S, McGlone M, Holleran Steiker LK, DeSalvo K, Bernhardt J, Pretorius K. (2020). Development of a health communication campaign to promote the Texas prescription monitoring program. Health Mark Q. 37(3):222-231. DOI: 10.1080/07359683.2020.1802967.
*Peterson J, Barner J, Lai P, Garza A, Hinds A, Nguyen M, Hill LG, Gums T. (2020). Impact of physician-pharmacist covisits at a primary care clinic in patients with uncontrolled diabetes. J Pharm Pract. 33(3):321-325. DOI: 10.1177/0897190018807374.
*Hill LG, Holleran Steiker LK, Mazin L, Kinzly ML. (2020). Implementation of a collaborative model for opioid overdose prevention on campus. J Am Coll Health. 68(3):223-226. DOI: 10.1080/07448481.2018.1549049.
*Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR. (2020). Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. J Am Pharm Assoc. 60:81-86. DOI: 10.1016/j.japh.2019.09.007.
*Hill LG, Laguado SA. (2019). Guidance for male mentors to support the safety and success of female mentees. Am J Pharm Educ. 83(10):7533. DOI: 10.5688/ajpe7533.
*Hill LG, Evoy KE, Reveles KR. (2019). Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. J Am Pharm Assoc. 59(6):779-782. DOI: 10.1016/j.japh.2019.06.019.
*Hill LG, Reveles KR, Evoy KE. (2019). State-level approaches to expanding pharmacists’ authority to dispense naloxone may affect accessibility. JAMA Intern Med. 179(10):1442-1443. DOI: 10.1001/jamainternmed.2019.3653.
*Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. (2018). Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. JAMA. 320(18):1934-1937. DOI: 10.1001/jama.2018.15892.
*Hill LG, Sanchez JP, Laguado SA, Lawson KA. (2018). Operation Naloxone: Overdose prevention service learning for student pharmacists. Curr Pharm Teach Learn. 10(10):1348-1353. DOI: 10.1016/j.cptl.2018.07.010.
*Murphy JE, Liles AM, Bingham AL, Chamberlin K, Dang D, Hill LG, Lee M, Leonard A, Lodise N, Rogers E. (2018). Interprofessional education: Principles and application. An update from the American College of Clinical Pharmacy. J Am Coll Clin Pharm. 1:e17-28. DOI: 10.1002/jac5.1025.
*Jordan RP, Bratberg J, Congdon HB, Cross LB, Hill LG, Marrs JC, McBane S, Lang WG, Ekoma JO. (2017). The report of the 2016-2017 advocacy standing committee. Am J Pharm Educ. 81(8):S10. DOI: 10.5688/ajpeS10.
*Han JK, Hill LG, Koenig ME, Das N. (2017). Naloxone counseling for harm reduction and patient engagement. Fam Med. 49(9):730-733.
*Corbo JM, DeLellis TM, Hill LG, Rindfuss SL. (2016). ACE inhibitors or ARBs to prevent CKD in patients with microalbuminuria. Am Fam Physician. 94(8).652-653.
*Hill LG, Chee JS, Haugh AJ, Wilson SA. (2015). Does time of day affect lipoprotein measurement independent of fasting state? Evidence-Based Practice. 18(7):11. DOI: 10.1097/01.EBP.0000541014.38985.c7.
*Hill LG, Dupuis KM. (2015). Compounded vancomycin solution for Clostridium difficile infection. Evidence-Based Practice. 18(7):2. DOI: 10.1097/01.EBP.0000541002.47570.d0.
*Hill LG. Lorcaserin and phentermine/topiramate: Two leaps forward in weight loss pharmacotherapy. (2013). Ann Pharmacother. 47(12):1740. DOI: 10.1177/1060028013513557.
Email address:
Phone:
Campus location:
US Mail Address:
The University of Texas at Austin
PHR 2.222G
2409 University Avenue, A1910
Austin, TX 78712